Introduction
============

Several theories have been presented regarding the pathogenesis of endometriosis; however, to date, the etiology and factors potentially involved in its development and progression remain poorly understood. Some authors have theorized that endometriosis should be considered a multifactorial disease involving genetic, hormonal, immunological, and environmental factors \[[@b1-cerm-2018-00416]\]. In particular, inflammatory processes are thought to play an important role in the development and progression of endometriosis, as abnormal levels of proinflammatory cytokines have been observed in the peritoneal fluid and serum of women with endometriosis \[[@b2-cerm-2018-00416]\].

Vitamin D is considered to be an important modulator of the immune system, and the potential role of vitamin D in endometriosis is of significant interest \[[@b3-cerm-2018-00416]\]. In particular, *in vitro* studies have demonstrated the anti-inflammatory, anti-proliferative, and anti-invasive effects of vitamin D in several immune-related pathologies, including rheumatoid arthritis \[[@b4-cerm-2018-00416]\], psoriasis \[[@b5-cerm-2018-00416]\], and cancer \[[@b6-cerm-2018-00416]\]. Evidence for a role of vitamin D in the pathogenesis of endometriosis is also beginning to emerge.

In the circulation, the majority of 25-hydroxyl vitamin D (25(OH)D) is bound to vitamin D-binding protein (VDBP). VDBP plays a major role in maintaining total and free 25(OH)D concentrations. Albumin is also a low-affinity carrier of 25(OH)D, which increases tissue availability. According to the free hormone hypothesis, only unbound vitamin D is physiologically active \[[@b7-cerm-2018-00416]\]; however, plasma total 25(OH)D concentrations, not free 25(OH)D levels, are used to determine vitamin D status, as free or unbound 25(OH)D comprises less than 0.1% of total 25(OH)D. Bioavailable 25(OH)D is defined as the combination of free and albumin-bound 25(OH)D or 25(OH)D that is not bound to VDBP, and represents up to 10% of total 25(OH)D \[[@b7-cerm-2018-00416]\]. In addition to transporting 25(OH)D, VDBP is also crucial for the conversion of 25(OH)D to its active form, 1,25(OH)D, and for the reabsorption of 25(OH)D metabolites in the kidneys. VDBP also has been shown to act as an actin scavenger, macrophage activator, and inflammatory marker \[[@b8-cerm-2018-00416]\], and VDBP levels have been found to vary by the degree of insulin resistance, liver and kidney disease, pregnancy, and inflammation \[[@b9-cerm-2018-00416]\].

Because 25(OH)D has been suggested to play an important pathological role in endometriosis, we hypothesized that serum concentrations of 25(OH)D and VDBP would vary with the severity of the disease. The aim of this study was to investigate 25(OH)D status via total 25(OH)D, bioavailable and free 25(OH)D, and serum VDBP levels in women with mild and advanced endometriosis.

Methods
=======

1. Study participants
---------------------

All participants in this study were patients admitted to Gyeongsang National University Hospital, Jinju, Korea from February 2017 to May 2018. All patients underwent laparoscopy to stage the severity of their endometriosis according to the Revised Classification of the American Society for Reproductive Medicine (ASRM) \[[@b10-cerm-2018-00416]\]. All patients were differentially diagnosed and staged based on a pathological review of the surgical specimens.

Patients in this study were divided into three groups: mild endometriosis (ASRM stage I/II), advanced endometriosis (ASRM stage III/IV), and healthy controls. Healthy controls were recruited from women who were at the facility for a health screening and did not report any symptoms of endometriosis. Whole-blood and serum samples were collected from nine patients with mild endometriosis, seven patients with advanced endometriosis, and 16 healthy controls.

This study was approved by the Institutional Review Board of the Gyeongsang National University Hospital (IRB No. GNUH 2017-01-004).

2. Serum total 25(OH)D and VDBP concentrations
----------------------------------------------

Each serum sample was aliquoted into two tubes and stored at −80°C until it could be analyzed for total 25(OH)D and VDBP levels. Serum total 25(OH)D concentrations were analyzed using the Elecsys vitamin D total kit with the Cobas e602 module (Roche Diagnostics, Mannheim, Germany), which is an electrochemiluminescent assay with ruthenium-labeled VDBP, biotin-labeled vitamin D, and streptavidin-coated microparticles. VDBP concentrations were measured using the Human Vitamin D BP Quantikine ELISA kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's protocol.

3. Calculation of bioavailable and free 25(OH)D
-----------------------------------------------

Concentrations of bioavailable and free 25(OH)D were calculated from the total 25(OH)D, VDBP, and serum albumin concentrations using the following equations \[[@b11-cerm-2018-00416],[@b12-cerm-2018-00416]\].

Bioavailable 25(OH)D =albumin-bound 25(OH)D+free 25(OH)D =(albumin×*K~albumin~*+1)×free 25(OH)D

Free

25

(

OH

)

D

=

--

b

\+

b

2

--

4

a

c

2

a

a

=

K

V

D

B

P

×

K

a

l

b

u

m

i

n

×

a

l

b

u

m

i

n

\+

K

V

D

B

P

b

=

K

V

D

B

P

×

V

D

B

P

--

K

V

D

B

P

×

t

o

t

a

l

25

(

O

H

)

D

\+

K

a

l

b

u

m

i

n

×

a

l

b

u

m

i

n

\+

1

c

=

--

total

25

(

OH

)

D

*K~VDBP~* \[for genotype--constant bioavailable 25(OH)D\]=0.7×10^9^ M^--1^

To calculate genotype-specific bioavailable 25(OH)D levels, the *GC* genotype-specific VDBP binding affinity (*K~VDBP1f~* , 1.12×10^9^ M^--1^; *K~VDBP1s~*, 0.6×10^9^ M^--1^; *K~VDBP2~*, 0.36×10^9^ M^--1^) was used instead of the generic KVDBP \[[@b13-cerm-2018-00416]\]. For heterozygous genotypes, the mean affinity for the two homozygotes was used (*K~VDBP1f/1s~*, 0.86×10^9^ M^--1^; *K~VDBP1f~*/2, 0.74×10^9^ M^--1^; *K~VDBP1s/2~*, 0.48×10^9^ M^--1^) \[[@b14-cerm-2018-00416]\]. In this study, bioavailable 25(OH)D referred to both genotype-constant and genotype-specific bioavailable 25(OH)D.

4. Statistical analysis
-----------------------

Continuous variables were presented as mean with standard deviation and median with interquartile range. The variables were tested for normality and homoscedasticity using the Shapiro-Wilk test and Leven F test, respectively. If variables satisfied normality and homoscedasticity, analysis of variance was used to compare the values among the three groups. Otherwise, the Kruskal-Wallis test was used. The Fisher exact test was used to compare the proportions of categorical variables by groups.

Correlation analysis was used to identify variables related to total 25(OH)D and VDBP levels. If the normality assumption was satisfied, Pearson correlation analysis was performed, and if not, Spearman correlation analysis was used.

Multivariate generalized additive modeling (GAM) was performed to identify the effects of total 25(OH)D and VDBP in the three groups. The variables included in the multivariate analysis were those that showed an association with total 25(OH)D or VDBP levels in the correlation analysis, with a *p*-value of 0.20 or less. Among the variables associated with total 25(OH)D and VDBP, if the correlation coefficient between the variables was more than 0.7, only one variable was included in the multivariate analysis to avoid the problem of multicollinearity. All analyses were conducted using R ver. 3.52 (R Foundation, Vienna, Austria). A two-sided test *p*-value \<0.05 was considered to indicate statistical significance.

Results
=======

[Table 1](#t1-cerm-2018-00416){ref-type="table"} shows the clinical characteristics of the study participants according to the severity of endometriosis. Gravidity (*p*=0.001) and parity (*p*=0.002) were significantly different across the three groups. There was no significant difference in age or place of residence (as a proxy for sunlight exposure) across the three groups.

The laboratory findings of the study participants are reported in [Table 1](#t1-cerm-2018-00416){ref-type="table"}. There were no significant differences in body mass index or serum albumin levels. The erythrocyte sedimentation rate (ESR), as an index of inflammation, increased as a function of endometriosis severity (*p*=0.051). C-reactive protein, another inflammatory marker, was not significantly different across the three groups. In addition, serum CA-125 levels were significantly different across the three groups (*p*=0.004) with higher levels observed in both groups with endometriosis than in healthy controls.

To confirm the relationships of total 25(OH)D and VDBP with other variables, correlation analysis was performed. The results showed that total 25(OH)D levels were positively correlated with gravidity (*r*=0.59, *p*\<0.001) and parity (*r*=0.51, *p*=0.003), but not with ESR (*r*=−0.32, *p*=0.071) and CA-125 (*r*=−0.06, *p*=0.724) ([Table 2](#t2-cerm-2018-00416){ref-type="table"}).

Multivariate GAM showed no significant relationship of vitamin D levels with endometriosis severity after adjusting for gravidity and ESR. However, total 25(OH)D levels were significantly correlated with gravidity (1.87; 95% confidence interval \[CI\], 0.12 −3.63; *p*=0.040).

VDBP showed no significant correlations with other variables ([Table 3](#t3-cerm-2018-00416){ref-type="table"}). In pairwise comparisons, serum levels of total 25(OH)D tended to show a negative relationship with the severity of endometriosis, but this relationship was not statistically significant across the three groups. Serum levels of bioavailable and free 25(OH)D did not differ according to the severity of endometriosis. However, the serum levels of total, bioavailable, and free 25(OH)D in the advanced endometriosis group were significantly lower than in the healthy control group (*p*=0.001, *p*=0.018, and *p*=0.049, respectively). For serum concentrations of VDBP, we found no significant differences between the healthy control group and either group defined in terms of endometriosis severity ([Figure 1](#f1-cerm-2018-00416){ref-type="fig"}).

Discussion
==========

As in many chronic diseases, vitamin D has long been proposed as an important modulator in the pathogenesis of endometriosis, but this possibility remains controversial and is under investigation \[[@b15-cerm-2018-00416]\]. Vitamin D also plays a role in the regulation of sex hormone steroidogenesis. In addition, increasing evidence suggests that 25(OH)D may play a regulatory role in symptoms associated with polycystic ovary syndrome. Vitamin D deficiency has been reported to contribute to the pathogenesis of endometriosis via its immunomodulatory and anti-inflammatory properties \[[@b16-cerm-2018-00416]\].

Previous studies that have investigated serum 25(OH)D levels according to the presence or absence of endometriosis have reported inconsistent findings. One study showed lower levels of 25(OH)D in patients with endometriosis \[[@b17-cerm-2018-00416]\]. A study by Harris et al. of women enrolled in the Nurses' Health Study II reported that predicted plasma 25(OH)D levels were inversely associated with endometriosis risk; the authors of that study recommended consumption of foods high in 25(OH)D to prevent endometriosis \[[@b18-cerm-2018-00416]\]. In contrast, other studies have reported nonsignificant elevations in 25(OH)D among women with endometriosis \[[@b19-cerm-2018-00416],[@b20-cerm-2018-00416]\]. Prior studies measured total 25(OH)D concentrations, but did not consider bioavailable or free 25(OH)D. Vitamin D also is known to show varying activity depending on the degree of binding with VDBP. To the best of our knowledge, few studies have investigated bioavailable and free 25(OH)D and VDBP according to the severity of endometriosis. Our study compared total, bioavailable, and free 25(OH)D concentrations, as well as VDBP concentrations, between women with mild and advanced endometriosis and healthy controls. In our study, total 25(OH)D tended to show an inverse relationship with the severity of the disease. This finding is consistent with a previous study that reported significantly lower total 25(OH)D concentrations in women with severe endometriosis than in both the healthy controls and in women with mild endometriosis \[[@b21-cerm-2018-00416]\].

An analysis of the clinical characteristics of patients enrolled in this study indicated that age and BMI did not differ across the three groups. We found that the number of pregnancies and the number of births were significantly lower in patients with more severe disease. This finding suggests that infertility is more common in patients with endometriosis, particularly in those with severe endometriosis. However, the exact relationship between endometriosis and infertility remains unclear \[[@b22-cerm-2018-00416]\].

In our study, ESR and CA-125 concentrations were higher in the endometriosis groups. ESR was different across the three groups in our study, and showed a significant tendency to increase with greater disease severity. This finding may be related to the varying extent of tissue destruction that occurs as endometriosis progresses. Our finding is consistent with a meta-analysis of CA-125 levels in the diagnosis of endometriosis, which suggested that serum CA-125 may be a useful biomarker for the noninvasive diagnosis of endometriosis \[[@b23-cerm-2018-00416]\]. However, meaningful correlations of total 25(OH)D levels with the ESR and CA-125 were not found. The correlation analysis showed that total 25(OH)D levels were positively correlated with gravidity and parity, but not with ESR and CA-125 ([Table 2](#t2-cerm-2018-00416){ref-type="table"}).

To investigate the effects of serum levels of total 25(OH)D and VDBP on the severity of endometriosis, we performed multivariate GAM. After adjusting for gravidity and ESR, total 25(OH)D and VDBP levels were not significantly related with endometriosis severity. However, total 25(OH)D levels were significantly correlated with gravidity. Our results suggest that serum concentration of total 25(OH)D was related to the number of births regardless of the concentration of VDBP. A number of articles have shown a relationship between childbirth and bone mineral density (BMD), although another report suggested that there is no association between the number of children and BMD. Another study suggested that BMD may be reduced by having a large number of children and a long breastfeeding period \[[@b24-cerm-2018-00416]\]. In the present study, higher serum total 25(OH)D levels were associated with higher gravidity. For this reason, the authors suggest that vitamin D may have increased to compensate for lower BMD. The reason for this should be studied in the future research.

A limitation of our study was the small sample of enrolled patients in each group. Our study also did not account for sunlight exposure. We also did not follow up with patients after treatment, which would have helped to clarify etiologic factors in their disease. In conclusion, these results indicate that vitamin D and VDBP levels were not associated with the severity of endometriosis.
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![Pairwise comparison of serum (A) total, (B) bioavailable, (C) free 25-hydroxyl vitamin D (25(OH)D), and (D) vitamin D-binding protein (VDBP) according to disease severity. EMT, endometriosis (mild, American Society for Reproductive Medicine \[ASRM\] stage I and II; advanced, ASRM stage III and IV).](cerm-2018-00416f1){#f1-cerm-2018-00416}

###### 

Demographic and clinical factors of participants by group

  Variable                       Healthy control (n = 16)   Mild EMT (n = 9)          Advanced EMT (n = 7)      *p*-value^[a)](#tfn1-cerm-2018-00416){ref-type="table-fn"}^
  ------------------------------ -------------------------- ------------------------- ------------------------- -------------------------------------------------------------
  Age (yr)                                                                                                      0.304
   Mean±SD                       37.31 ± 6.35               35.44 ± 7.20              32.57 ± 6.95              
   Median (IQR)                  38.50 (32.00--42.25)       36.00 (32.00--42.00)      32.00 (29.00--36.50)      
  BMI (kg/m^2^)                                                                                                 0.236
   Mean±SD                       21.69 ± 2.29               21.28 ± 2.09              23.77 ± 2.92              
   Median (IQR)                  21.50 (19.93--23.75)       21.80 (20.00--22.90)      23.70 (22.75--24.35)      
  Gravidity                                                                                                     0.001
   Mean±SD                       2.62 ± 1.09                1.22 ± 1.09               0.57 ± 0.79               
   Median (IQR)                  2.50 (2.00--3.00)          1.00 (0.00--2.00)         0.00 (0.00--1.00)         
  Parity                                                                                                        0.002
   Mean±SD                       1.88 ± 0.72                1.11 ± 0.93               0.43 ± 0.53               
   Median (IQR)                  2.00 (1.00--2.00)          1.00 (0.00--2.00)         0.00 (0.00--1.00)         
  Place of residence, n (%)                                                                                     0.882
   Urban                         12 (52.2)                  6 (26.1)                  5 (21.7)                  
   Rural                         4 (44.4)                   3 (33.3)                  2 (22.2)                  
  Albumin (mg/dL)                                                                                               0.935
   Mean±SD                       4.66 ± 0.29                4.63 ± 0.26               4.60 ± 0.29               
   Median (IQR)                  4.70 (4.40--4.90)          4.60 (4.40--4.80)         4.60 (4.45--4.85)         
  ESR (mm/hr)                                                                                                   0.051
   Mean±SD                       10.70 ± 8.26               15.76 ± 11.97             24.70 ± 12.02             
   Median (IQR)                  8.75 (4.17--14.43)         14.00 (7.00--27.00)       29.00 (20.95--31.00)      
  CRP (mg/L)                                                                                                    0.841
   Mean±SD                       0.78 ± 1.31                3.52 ± 7.62               2.30 ± 4.46               
   Median (IQR)                  0.20 (0.10--0.72)          0.20 (0.10--0.50)         0.40 (1.10--1.55)         
  CA-125 (IU/mL)                                                                                                0.004
   Mean±SD                       23.87 ± 16.21              192.22 ± 335.01           140.97 ± 137.62           
   Median (IQR)                  20.30 (13.97--27.10)       39.40 (23.50--161.00)     102.00 (41.90--182.45)    
  Total 25(OH)D (ng/mL)                                                                                         0.006
   Mean±SD                       16.96 ± 4.71               14.17 ± 7.62              8.91 ± 1.67               
   Median (IQR)                  18.09 (13.60--18.64)       12.50 (9.70--21.30)       9.30 (8.45--9.40)         
  Bioavailable 25(OH)D (ng/mL)                                                                                  0.062
   Mean±SD                       1.95 ± 0.79                2.45 ± 1.36               1.30 ± 0.35               
   Median (IQR)                  1.75 (1.53--2.00)          2.67 (1.36--3.08)         1.22 (1.07--1.53)         
  Free 25(OH)D (ng/mL)                                                                                          0.085
   Mean±SD                       4.81 ± 1.74                6.30 ± 3.28               3.36 ± 1.00               
   Median (IQR)                  4.32 (3.94--5.03)          7.15 (3.40--8.51)         3.29 (2.51--4.27)         
  VDBP (ng/mL)                                                                                                  0.241
   Mean±SD                       169.20 ± 36.31             161.25 ± 53.09            198.34 ± 42.54            
   Median (IQR)                  169.77 (142.02--196.08)    156.05 (124.05--179.57)   205.47 (173.09--218.44)   

EMT, endometriosis (mild, American Society for Reproductive Medicine \[ASRM\] stage I and II; advanced, ASRM stage III and IV); SD, standard deviation; IQR, interquartile range; BMI, body mass index; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; 25(OH)D, 25-hydroxyl vitamin D; VDBP, vitamin D-binding protein.

*p*-value \<0.05 is considered to indicate statistical significance.

###### 

Correlations between demographic and clinical factors and total 25(OH)D and VDBP levels

  Variable   Total 25(OH)D         VDBP                                 
  ---------- --------------------- ---------- ------------------------- -------
  Age        0.21                  0.24       --0.34                    0.056
  BMI        --0.13                0.467      0.12                      0.531
  Gravity    0.59                  \< 0.001   --0.13                    0.481
  Parity     0.51                  0.003      --0.23                    0.209
  Place                            0.63                                 0.869
   Urban     13.27 (9.35--18.41)              162.81 (146.16--210.54)   
   Rural     13.71 (9.7--18.50)               176.80 (134.80--186.80)   
  Albumin    --0.07                0.7        --0.14                    0.439
  ESR        --0.32                0.071      0.34                      0.055
  CRP        --0.32                0.071      0.34                      0.055
  CA-125     --0.06                0.724      0.14                      0.448
  VDBP       0.03                  0.077                                

25(OH)D, 25-hydroxyl vitamin D; VDBP, vitamin D-binding protein; BMI, body mass index; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.

###### 

Multivariate generalized additive modeling for total 25(OH)D and VDBP levels

                     Total 25(OH)D             VDBP                                
  ------------------ ------------------------- ------- --------------------------- -------
  Group                                                                            
   Healthy control   0.00                      \-      0.00                        \-
   Mild EMT          0.20 (--4.68 to 5.07)     0.935   --9.17 (--52.82 to 34.49)   0.672
   Advanced EMT      --2.46 (--8.82 to 3.90)   0.437   23.8 (--34.64 to 82.25)     0.414
  Age                                                  --2.45 (--5.79 to --0.9)    0.151
  Gravidity          1.87 (0.12 to 3.63)       0.040                               
  Parity                                               10.69 (--19.3 to 40.68)     0.474
  ESR                --0.12 (--0.30 to 0.06)   0.177   0.81 (--0.87 to 2.49)       0.337

25(OH)D, 25-hydroxyl vitamin D; VDBP, vitamin D-binding protein; CI, confidence interval; EMT, endometriosis (mild, American Society for Reproductive Medicine \[ASRM\] stage I and II; advanced, ASRM stage III and IV); ESR, erythrocyte sedimentation rate.
